NETCast Promising Advances in NEC Research and Treatment
May 27, 2025
Dr. Renuka Iyer, a GI and neuroendocrine oncologist, and Dr. Aman Chauhan, a leader in neuroendocrine tumor research, share insights on groundbreaking advancements in neuroendocrine carcinoma treatments. They delve into the biological distinctions between pulmonary and extrapulmonary types and discuss innovative therapies like DLL3 targeting and oncolytic virus studies. The importance of clinical trials and tumor profiling is emphasized, highlighting their critical role in improving patient outcomes and presenting new therapeutic options for challenging cases.
AI Snips
Chapters
Transcript
Episode notes
Neuroendocrine Carcinoma Differences
- Pulmonary and extrapulmonary neuroendocrine carcinomas differ significantly in biology, risk factors, and presentation.
- Lung small cell cancers often relate to smoking and show early brain metastases, while extrapulmonary types vary by organ and may have later brain involvement.
Advances in Small Cell Lung Treatment
- First-line treatment for extensive stage small cell lung cancer includes platinum-etoposide chemotherapy with immunotherapy.
- Emerging treatments like DLL3 targeting agents may soon move to frontline therapy for improved outcomes.
Manage Extrapulmonary NEC Strategically
- Screen newly diagnosed advanced extrapulmonary neuroendocrine carcinoma patients for DLL3 expression to identify trial options.
- Tailor treatment intent to patient status: curative trials, palliative care, or tailored therapies for rare mutations.